🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Recruitingn/aAges 18 Years - anyAllOhio State University
NCT07702461 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide \[Ozempic, Wegovy, Rybelsus\], liraglutide \[Saxenda, Victoza\], or tirzepatide \[Mounjaro, Zepbound\]) perform resistance (strength) training before and after starting their medication. GLP-1 medications are being prescribed more and more often to help people manage type 2 diabetes and lose weight. These medications work well, but a known side effect is that people can lose lean (muscle) tissue along with fat. Losing muscle can make it harder to move, do everyday tasks, and stay strong as we age. Resistance training, things like lifting weights, using resistance bands, or doing push-ups and squats, is the most effective way to keep and build muscle. Yet most adults in the United States do not meet the recommended amount of resistance training, and very little is known about the resistance t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult aged 18 years or older * Currently taking a GLP-1 receptor agonist medication * On the GLP-1 receptor agonist for at least 3 months * Using the GLP-1 receptor agonist for type 2 diabetes, overweight or obesity, and/or weight management (self-reported) * Stable GLP-1 receptor agonist dose for the past 4 to 8 weeks * Able to read and respond to the survey in English * Willing and able to provide informed consent electronically Exclusion Criteria: * Currently or planning to become pregnant * Planned bariatric surgery within the next 3 months * Recent bariatric surgery (within the past 3 months) or other conditions that substantially alter resistance training capacity (e.g., advanced cancer cachexia, severe mobility-limiting conditions) * Unable to read or respond to the survey in English
💊

What it tests

  • Glucagon-Like Peptide-1 Agonist (GLP-1)
📍

Where

1 site
The Ohio State University
Columbus, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy